Page 334 - Binder2

Because the core requirements are simple: a clean growing
space, a gene construct, and access to basic processing
tools like freeze-dryers and capsule fillers.

This shift enables a modular, mobile, and resilient
production model that can respond to demand locally—not
just globally.

A New Kind of Facility

Instead of multi-story plants with sterile corridors and
redundant HVAC systems, imagine a regional therapeutic
greenhouse:

● Designed to grow genetically engineered lettuce
expressing insulin or antibodies.
● Integrated with AI-controlled lighting, nutrients,
and environmental parameters.
● Staffed by technicians with agricultural training, not
pharmaceutical degrees.

These facilities could be as small as a shipping container or
as large as a vertical farm—scaled to need, not capital.
They can be built quickly, operated at low cost, and located
closer to the populations they serve.

Leapfrogging the Biologics Gap

For many nations, access to modern biologics remains
prohibitively limited—not because of the science, but
because of the infrastructure. Countries without high-grade
GMP facilities can’t produce monoclonals. They must

332